Structure Therapeutics Inc. (GPCR)
D
Pipeline Grade
Financial Position (from SEC Filings)
$316.2M
Cash & Equivalents
$15.2M
Quarterly Burn Rate
$3,919M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
| 2026-09-01 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07169942 | Aleniglipron Phase 2 Body Composition Study | PHASE2 | Active Not Recruiting | 71 |
| NCT07400588 | Aleniglipron Phase 2 in Type 2 Diabetes Mellitus | PHASE2 | Active Not Recruiting | 58 |
| NCT06693843 | A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Partici... | PHASE2 | Active Not Recruiting | 220 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.